MARC details
| 000 -LEADER |
|---|
| fixed length control field |
07260cam a2200397 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
1110656258 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20231227175128.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS |
|---|
| fixed length control field |
m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr ||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
190712s2020 nju rb 001 0 eng |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| Canceled/invalid ISBN |
9781119413417 |
| 035 ## - SYSTEM CONTROL NUMBER |
|---|
| System control number |
(OCoLC)1110656258 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
DLC |
| Language of cataloging |
eng |
| Description conventions |
rda |
| Transcribing agency |
DLC |
| Modifying agency |
OCLCO |
| -- |
YDX |
| -- |
DG1 |
| -- |
YDX |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
pcc |
| 050 04 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RM301.5 |
| Item number |
.P53 2020 |
| 060 10 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
|---|
| Classification number |
QV 771 |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.7 |
| Edition number |
23 |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Strom, Brian L., |
| Relator term |
editor |
| 130 0# - MAIN ENTRY--UNIFORM TITLE |
|---|
| Uniform title |
Pharmacoepidemiology (Strom) |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Pharmacoepidemiology / |
| 250 ## - EDITION STATEMENT |
|---|
| Edition statement |
Sixth edition |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Hoboken, NJ : |
| Name of producer, publisher, distributor, manufacturer |
Wiley-Blackwell, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2020 |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references and index |
| 505 ## - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Contributors x Preface xix Acknowledgments xxiii Part I Introduction 1 1 What is Pharmacoepidemiology? 3; Brian L. Strom 2 Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies 27; Jeffrey S. Barrett 3 Basic Principles of Clinical Epidemiology Relevant to Pharmacoepidemiologic Studies 44; Brian L. Strom 4 Sample Size Considerations for Pharmacoepidemiologic Studies 60; Brian L. Strom 5 When Should One Perform Pharmacoepidemiologic Studies? 71; Brian L. Strom Part II The Role of Pharmacoepidemiology in Different Sectors 81 6 The Role of Pharmacoepidemiology in the Healthcare System and Academia 83; Joshua J. Gagne and Jerry Avorn 7 The Role of Pharmacoepidemiology in Industry 98; Nicolle M. Gatto, Rachel E. Sobel, Jamie Geier, Jingping Mo, Andrew Bate, and Robert F. Reynolds 8 The Role of Pharmacoepidemiology in Regulatory Agencies 126; Gerald J. Dal Pan, June Raine, and Shinobu Uzu 9 Pharmacoepidemiology and the Law 140; Aaron S. Kesselheim and Kerstin N. Vokinger Part III Sources of Data for Pharmacoepidemiology Research 165 Part IIIa Spontaneous Reporting 167 10 Postmarketing Spontaneous Pharmacovigilance Reporting Systems 169; Gerald J. Dal Pan, Marie Lindquist, and Kate Gelperin Part IIIb Electronic Data Systems 203 11 Overview of Electronic Databases in Pharmacoepidemiology 205; Brian L. Strom 12 Encounter Databases 211; Tobias Gerhard, Yola Moride, Anton Pottegård, and Nicole Pratt 13 Electronic Health Record Databases 241; Daniel B. Horton, Harshvinder Bhullar, Lucy Carty, Francesca Cunningham, Alexis Ogdie, Janet Sultana, and Gianluca Trifiro 14 Inpatient Databases 290; James A. Feinstein, Peter K. Lindenauer, Chris Feudtner, and Brian T. Fisher Part IIIc Studies Involving Ad Hoc Data Collection 305 15 Event Monitoring in the UK 307; Vicki Osborne and Saad A.W. Shakir 16 Primary Data Collection for Pharmacoepidemiology 342; Nancy A. Dreyer, Ana Filipa Macedo, and Priscilla Velentgas Part IIId Choosing a Data Source 355 17 Choosing among the Available Data Sources for Pharmacoepidemiology Research 357; Brian L. Strom Part IV Selected Applications of Pharmacoepidemiology 373 18 Studies of Drug Utilization 375; Bj örn Wettermark, Vera Vlahović-Palčevski, David Lee, and Ulf Bergman 19 Evaluating and Improving Physician Prescribing 411; Christine Y. Lu, the late Sumit R. Majumdar, Helene Lipton, and Stephen B. Soumerai 20 Pharmacoepidemiologic Studies of Vaccine Safety 437; Robert T. Chen, Jason M. Glanz, and Tom T. Shimabukuro 21 Epidemiologic Studies of Medical Devices: Methodologic Considerations for Implantable Devices 496; Danica Marinac-Dabic, Sharon-Lise Normand, Art Sedrakyan, and Thomas P. Gross 22 Research on the Effects of Medications in Pregnancy and in Children 524; Daniel B. Horton, Sonia Hernandez-Diaz, Tamar Lasky, and Krista F. Huybrechts 23 Study of Biologics and Biosimilars 561; Jeffrey R. Curtis and James D. Lewis 24 Risk Management 581; Claudia Manzo, Emil Cochino, Lubna Merchant, and Giampiero Mazzaglia 25 Distributed Networks of Databases Analyzed Using Common Protocols and/or Common Data Models 617; Sengwee Toh, Nicole Pratt, Olaf Klungel, Joshua J. Gagne, and Robert W. Platt 26 Comparative Effectiveness Research 639; Soko Setoguchi and Ian Chi Kei Wong 27 Data Mining and Other Informatics Approaches to Pharmacoepidemiology 675; Andrew Bate, Gianluca Trifirò, Paul Avillach, and Stephen J.W. Evans 28 Pharmacoepidemiologic Research on Drugs of Abuse 701; Jana McAninch, Alex Secora, Cynthia Kornegay, and Judy Staffa Part V Selected Special Methodologic Issues in Pharmacoepidemiology 723 29 Assessing Causation from Case Reports 725; Judith K. Jones, Bernard Bégaud, and Elyse Kingery 30 Molecular Pharmacoepidemiology 746; Christine Y. Lu and Stephen E. Kimmel 31 Bioethical Issues in Pharmacoepidemiologic Research 772; Laura E. Bothwell, Annika Richterich, and Jeremy Greene 32 The Use of Randomized Controlled Trials in Pharmacoepidemiology 792; Robert F. Reynolds, Samuel M. Lesko, Nicolle M. Gatto, Tjeerd P. Van Staa, and Allen A. Mitchell 33 The Use of Pharmacoepidemiology to Study Beneficial Drug Effects 813; Brian L. Strom and the late Kenneth L. Melmon 34 Pharmacoeconomics: The Economics of Pharmaceuticals 837; Kevin A. Schulman 35 Benefit-Risk Assessments of Medical Treatments 867; Bennett Levitan, Rachael DiSantostefano, and Scott Evans 36 The Use of Metaanalysis in Pharmacoepidemiology 897; Jesse A. Berlin, Brenda J. Crowe, H. Amy Xia, and Stephen J.W. Evans 37 Validity of Drug and Diagnosis Data in Pharmacoepidemiology 948; Mary Elizabeth Ritchey, Suzanne L. West, and George Maldonado 38 Studies of Medication Adherence 991; Julie Lauffenburger, Trisha Acri, and Robert Gross 39 Risk Evaluation and Communication 1010; Susan J. Blalock, Rebecca Dickinson, and Peter Knapp 40 Methods for Studying the Health Effects of Drug-Drug Interactions 1030; Sean Hennessy, Charles E. Leonard, Joshua J. Gagne, James H. Flory, Colleen M. Brensinger, and Warren B. Bilker 41 The Pharmacoepidemiology of Medication Errors 1046; Hanna M. Seidling and David W. Bates 42 Patient Engagement and Patient-Reported Outcomes 1061; Esi M. Morgan 43 Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies 1078; Sebastian Schneeweiss and Samy Suissa Part VI Conclusion 1109 44 The Future of Pharmacoepidemiology 1111; Brian L. Strom, Stephen E. Kimmel, and Sean Hennessy Appendix A Sample Size Tables 1123 Appendix B Glossary 1141 Index 1155 |
| 506 ## - RESTRICTIONS ON ACCESS NOTE |
|---|
| Terms governing access |
Available to OhioLINK libraries |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
"This classic, field-defining textbook, now in its sixth edition, provides the most comprehensive guidance available for anyone needing up-to-date information in pharmacoepidemiology. This edition has been fully revised and updated throughout and continues to provide a rounded view on all perspectives from academia, industry and regulatory bodies, addressing data sources, applications and methodologies with great clarity"-- |
| Assigning source |
Provided by publisher |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmacoepidemiology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmacology. |
| Authority record control number |
http://id.loc.gov/authorities/subjects/sh85100599 |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmacoepidemiology |
| Authority record control number |
http://id.loc.gov/authorities/subjects/sh89004031 |
| General subdivision |
Methodology. |
| Authority record control number |
http://id.loc.gov/authorities/subjects/sh99001902 |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmacoepidemiology |
| General subdivision |
methods. |
| Authority record control number |
https://id.nlm.nih.gov/mesh/D017891Q000379 |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Kimmel, Stephen E., |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Hennessy, Sean, |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Ohio Library and Information Network. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
Books |
